CYAD-203

N/A

Report date: 2024/12/02 13:49:58

Base Information

Drug NameCYAD-203

Drug Alias NameAnti-NKG2D CAR-T therapy (Celyad Oncology)CYAD-203

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionInterleukin-18 replacementsNKG2D ligands modulators

TargetsInterleukin 18NKG2D ligands

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgium

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCelyad Oncology SA

China Registration ClassN/A

Develop Information

Active CompaniesCelyad Oncology SA

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A